Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months of treatment, he developed watery diarrhea and cramping abdominal pain. Follow-up positron emission tomography-computed tomography scan showed complete metabolic resolution of the disease; however, there is bowel wall thickening and colonic distension with corresponding increased fluorodeoxyglucose uptake. These findings are related to immune-related adverse event associated with nivolumab treatment, i.e., secondary enterocolitis. These adverse events can be successfully treated if timely and appropriately diagnosed.
Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis
18 F-FDG PET-CT images showed bowel wall thickening and colonic distension with corresponding increased tracer uptake [ Figure 1 ]. Although compare to prior study, there is complete metabolic resolution of prior hypermetabolic lesions are noted. Baseline and follow-up scans after nivolumab therapy are shown in Figure 2 . In the current study, the findings in the bowel are likely related to side effects of immunotherapy inducing secondary enterocolitis. Other causes like drug (e.g., metformin)-induced nonspecific uptake in the bowel is excluded.
Nivolumab is an ICI, is a humanized anti-programmed death-1 (PD-1) monoclonal antibody that is used as second-line therapy in various types of cancer such as melanoma, non-small cell lung cancer, renal cancer, Hodgkin's lymphoma, urothelial cancer, and head and neck cancers. [1, 2] Recently, nivolumab has demonstrated high (64%-87%) response rates in relapsed or refractory Hodgkin's lymphoma. [3] Nivolumab may activate T cells to develop antitumor effects, but this immune activation sometimes causes immune-related adverse events, such as pneumonitis, hepatitis, and enterocolitis. [4] Sometimes, these adverse events are serious and life-threatening, which require timely patient management and adequate therapeutic decisions.
ICIs, nivolumab is associated with many immune-regulated adverse events including nausea, abdominal pain, and diarrhea. Diarrhea is observed in about one-third of patients. It usually occurs in the 3 rd month of therapy. Diarrhea may be infectious or autoimmunological. About 8%-22% of patients receiving immunotherapy develop autoimmunological enterocolitis.
[5] Clinical symptoms of enterocolitis include mixed watery and bloody diarrhea and cramping pain. [6] Enterocolitis can be managed with cessation of nivolumab and administration of intravenous corticosteroid therapy or infliximab therapy in severe cases,
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For reprints contact: reprints@medknow.com like in our case. [7] 18 F-FDG PET-CT is standard of care for the staging, monitoring of response to therapy, and detection of disease recurrence for Hodgkin's disease and non-Hodgkin's lymphomas. [8, 9] 18 F-FDG PET-CT can be used to identify regions of active inflammation in ulcerative colitis. [10] ICI is a potentially important therapeutic agent for refractory and relapsed Hodgkin's lymphomas. [11] As the use of ICIs in cancer therapy increases, therefore immune-related adverse events are frequently identified on 18 F-FDG PET-CT, which may lead to early diagnosis, close clinical follow-up, and appropriate clinical management of immune-related adverse events.
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